Oncotype DX Breast Cancer Testing

East Sussex Healthcare NHS Trust · Awarded

Buyer
East Sussex Healthcare NHS Trust
Status
Awarded
Country
United Kingdom
Region
England
Sector
Professional Services
Reference
UK-CFA-ocds-b5fd17-6952487a-f7d5-42df-ae7a-052feb2a20e7
Published
2026-03-03
Deadline
2026-02-04

Tender summary

Oncotype DX is a validated genomic assay recommended by NICE (DG34) for guiding chemotherapy decisions in specific cohorts of early breast cancer. It provides a Recurrence Score that stratifies patients into groups where chemotherapy is beneficial versus where endocrine therapy alone is sufficient. Additional information: This is a call off contract from framework 2023/S 000-028831 based on previous contracts usage.

This is a public summary of a procurement notice. Dates and status reflect the notice held by BidScout; check the full notice before bidding.

Full tender details have a three-minute guest preview for open opportunities. AI insights require registration.

Register for full access

IT tenders · Construction tenders · Sitemap